From the Department of Public Health and Social Sciences/Geriatrics
(L.K., M.B., H.L.) and Department of Clinical Physiology, Uppsala University,
Uppsala (B.A.); Department of Clinical Neurosciences, Karolinska Institute,
Stockholm (H.N.); and Department of Internal Medicine, Uppsala (L.L.)
(Sweden).
Correspondence to Dr Lena Kilander, Department of Public Health and Caring Sciences/Geriatrics, PO Box 609, SE-751 25 Uppsala, Sweden.
MethodsThis was a cross-sectional study based on a cohort of 952
community-living men, aged 69 to 75 years, in Uppsala, Sweden.
Cognitive functions were assessed by the MiniMental State Examination
and the Trail Making Tests, and a composite z score was
calculated. The relation between atrial fibrillation and cognitive
z score was analyzed, with stroke and other
vascular risk factors taken into account.
ResultsAll analyses were adjusted for age, education,
and occupational level. Men with atrial fibrillation (n=44) had lower
mean adjusted cognitive z scores (-0.26±0.11) than men
without atrial fibrillation (+0.14±0.03; P=0.0003). The
exclusion of stroke patients did not alter this relationship; the mean
cognitive z score was -0.24±0.12 in the 36 men with
atrial fibrillation and +0.17±0.03 in those without atrial
fibrillation (P=0.0004), corresponding to a difference
of 0.4 SDs between groups. Adjustments for 24-hour
diastolic blood pressure and heart rate, diabetes, and
ejection fraction did not change this relationship. Men with atrial
fibrillation who were treated with digoxin (n=27) performed markedly
better (-0.05±0.21) than those without treatment (n=9; -1.14±0.34;
adjusted P=0.0005). Previous myocardial infarction was
not associated with impaired cognitive results.
ConclusionsIn these community-living elderly men, we found an
association between atrial fibrillation and low cognitive function
independent of stroke, high blood pressure, and diabetes.
Interventional studies are needed to answer the question of whether
optimal treatment of atrial fibrillation may prevent or postpone
cognitive decline and dementia.
Cardiovascular Factors
Cognitive Function
Statistical Analysis
Description of the Study Cohort
Characteristics of Men With Stroke and Atrial Fibrillation
Confounding Factors
Cognitive Function in Atrial Fibrillation and Stroke
Digoxin Treatment and Cognitive Function
In the Rotterdam Study, stroke-free women with atrial fibrillation had
a higher risk of dementia and of cognitive impairment without dementia,
defined as performance in the MMSE <26
points.11 This is in concordance with our
results, but the difference in the MMSE score between men with and
without atrial fibrillation was quite small. Measurements of
subcorticofrontal functions, such as the TMTs, may be even more
sensitive than the MMSE in detecting vascular cognitive decline. This
has been indicated in neuroimaging studies in which white matter
lesions were associated with impaired results in the
TMTs.10 12 13
We did not find any associations between impaired cognitive
performance and other markers of cardiac disease, such as
previous myocardial infarction or low ejection fraction. This is in
contrast to other reports in which myocardial infarction has been
linked to poorer cognitive performance,14
to dementia in elderly women,15 and to
development of dementia after stroke in subjects with multiple cerebral
infarctions.16 However, in the
Cardiovascular Health Study, in which 3301 subjects
were examined with MRI, white matter lesions were related to high
systolic BP but not to coronary heart
disease.17
In the absence of manifest cerebrovascular disease, how may atrial
fibrillation be linked to impaired cognitive function? Are they
parallel markers of exposure to atherosclerotic factors, or is there a
causal relationship? A reverse causation does not seem plausible. These
cross-sectional findings can only be used as a basis for speculations
on possible pathophysiological mechanisms. The
relation between atrial fibrillation and manifest stroke is well
established.18 Atrial fibrillation has also been
associated with silent lacunar infarcts in elderly patients without
previous stroke or carotid lesions,19 and it may
be a more common cause of silent embolic cerebrovascular lesions than
previously assumed. Myocardial dysfunction may also cause periodic
disability in maintaining cerebral blood flow, with subsequent
ischemic lesions. Results from a neuropathological study
suggested that a failing heart may contribute to dementia through
episodes of insufficient cerebral blood flow in the combination of
small-vessel stenosis and intermittent BP
fall.20 However, in our population, neither low
systolic function, low BP, nor extreme nocturnal
dipping2 was associated with lower cognitive
performance. Interestingly, digoxin treatment in atrial
fibrillation was associated with better performance. This
relation is unlikely to be due to biased recall, since cognitive
performance did not differ between users and nonusers
of other medications. However, differences in baseline cognitive level
might determine type of treatment and adherence to medical
controls. Speculatively, regularization of cardiac rhythm might
prevent minor cerebral ischemic lesions, but this hypothesis is
a subject for a randomized trial.
Impaired cognitive function is the most sensitive and specific outcome
measurement of cerebral target organ damage. Our results add support to
a relation between vascular risk factors and cognitive impairment. This
may have implications not only for vascular dementia but also for
neurodegenerative dementia disorders. In the Rotterdam Study, atrial
fibrillation was linked to Alzheimer's disease as well as to
vascular dementia.11 Alzheimer's disease
and vascular dementia in the very elderly may have common etiologic
pathways, eg, atrial fibrillation and
hypertension.21 We conclude that further studies
are needed to investigate whether treatment of atrial
fibrillation22 and other risk factors might
prevent or postpone dementia.
Received March 12, 1998;
revision received June 8, 1998;
accepted June 8, 1998.
2.
Kilander L, Nyman H, Boberg M, Hansson L, Lithell H.
Hypertension is related to cognitive impairment: a 20-year follow-up of
999 men. Hypertension. 1998;31:780786.
3.
Hedstrand H. A Study of Middle-Aged Men With
Particular Reference To Risk Factors for Cardiovascular
Disease [thesis]. Uppsala, Sweden: Uppsala
University; 1975.
4.
Lithell H, Åberg H, Selinus I, Hedstrand H. The
Primary Preventive Study in Uppsala: fatal and non-fatal
myocardial infarction during a 10-year follow-up of a middle-aged male
population with treatment of high-risk individuals. Acta Med
Scand. 1984;215:403409.[Medline]
[Order article via Infotrieve]
5.
National Diabetes Data Group. Classification and
diagnosis of diabetes mellitus and other categories of glucose
intolerance. Diabetes. 1979;28:10391057.[Medline]
[Order article via Infotrieve]
6.
Andrén B. Left
Ventricular Morphology and Function in a Population Sample
of Elderly Men [thesis]. Uppsala, Sweden:
Uppsala University; 1996.
7.
Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems
in echocardiographic volume determinations:
echocardiographic-angiographic correlations in the
presence or absence of asynergy. Am J Cardiol. 1976;37:711.[Medline]
[Order article via Infotrieve]
8.
Lezak M. Neuropsychological Assessment. 3rd
ed. New York, NY: Oxford University Press; 1995.
9.
Folstein MF, Folstein SE, McHugh PR. "Mini-Mental
State": a practical method for grading the cognitive state of
patients for the clinician. J Psychiatr Res. 1975;12:189198.[Medline]
[Order article via Infotrieve]
10.
Breteler M, van Amerongen N, van Swieten J, Claus J,
Grobbee D, van Gijn J Hofman A, van Harskamp F. Cognitive correlates of
ventricular enlargement and cerebral white matter lesions
on magnetic resonance imaging. Stroke. 1994;25:11091115.[Abstract]
11.
Ott A, Breteler M, de Bruyne M, van Harskamp F, Grobbee
D, Hofman A. Atrial fibrillation and dementia in a population-based
study: the Rotterdam Study. Stroke. 1997;28:316321.
12.
Schmidt R, Fazekas F, Offenbacher H, Dusek T, Zach E,
Reinhart B, Grieshofer P, Freidl W, Eber B, Schumacher M, Koch M,
Lechner H. Neuropsychologic correlates of MRI white matter
hyperintensities: a study of 150 normal volunteers.
Neurology. 1993;43:24902494.
13.
DeCarli C, Murphy DGM, Tranh M, Grady CL, Haxy JV,
Gillette JA, Salerno JA, Gonzales-Aviles A, Horwitz B, Rapoport SI,
Schapiro MB. The effect of white matter hyperintensity volume on brain
structure, cognitive performance, and cerebral
metabolism of glucose in 51 healthy adults.
Neurology. 1995;45:20772084.
14.
Breteler M, Claus J, Grobbee D, Hofman A.
Cardiovascular disease and distribution of cognitive
function in elderly people: the Rotterdam Study. BMJ. 1994;308:16041608.
15.
Aronson MK, Ooi WL, Morgenstern H, Hofner A, Masur D,
Crystal H, Frishman W, Fisher D, Katzman R. Women, myocardial
infarction, and dementia in the very old. Neurology. 1990;40:11021106.
16.
Gorelick PB, Brody JA, Cohen DC, Freely S, Levy P,
Dollear W, Forman H, Harris Y. Risk factors for dementia associated
with multiple cerebral infarcts a case-control analysis in
predominantly African-American hospital-based patients. Arch
Neurol. 1993;50:714720.
17.
Longstreth WT, Manolio TA, Arnold A, Burke GL, Bryan N,
Jungreis CA, Enright PL, O'Leary D, Fried L. Clinical correlates of
white matter findings on cranial magnetic resonance imaging of 3301
elderly people: the Cardiovascular Health Study.
Stroke. 1996;27:12741282.
18.
Wolf PA, Dawber TR, Thomas HE, Kannel WB.
Epidemiologic assessment of chronic atrial fibrillation and risk of
stroke: the Framingham Study. Neurology. 1978;28:973977.
19.
Zito M, Muscari A, Marini E, De Iorio A, Puddu GM,
Abate G. Silent lacunar infarcts in elderly patients with chronic
nonvalvular atrial fibrillation. Aging Clin Exp Res. 1996;8:341346.
20.
Englund E, Brun A, Gustafson L. A white-matter disease
in dementia of Alzheimer's type: clinical and
neuropathological correlates. Int J Geriatr Psychiatry. 1989;4:87102.
21.
Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson
L-A, Nilsson L, Persson G, Odén A, Svanborg A. 15-year
longitudinal study of blood pressure and dementia. Lancet. 1996;347:11411145.[Medline]
[Order article via Infotrieve]
22.
O'Connell JE, Gray CS. Atrial fibrillation and
cognitive impairment. Lancet. 1992;340:1169. Letter.
© 1998 American Heart Association, Inc.
Original Contributions
Atrial Fibrillation Is an Independent Determinant of Low Cognitive Function
A Cross-Sectional Study in Elderly Men
![]()
Abstract
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
Background and
PurposeCerebrovascular disease is increasingly recognized as a
cause of dementia and cognitive decline. We have previously reported an
association between hypertension and diabetes and low cognitive
function in the elderly. Atrial fibrillation is another main risk
factor for cerebrovascular disease. The aim of this study was to
investigate whether atrial fibrillation is associated with low
cognitive function in elderly men with and without previous
manifest stroke.
Key Words: atrial fibrillation cognition risk factors stroke
![]()
Introduction
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
Cognitive decline and dementia are major causes of
disability in the elderly. Cerebrovascular disease contributes to a
substantial part of all cases of dementia.1
Hypertension, diabetes, and atrial fibrillation are major risk factors
of stroke. We have previously reported that high 24-hour
diastolic blood pressure (BP) and diabetes were associated
with low cognitive performance in a cohort of stroke-free
elderly men.2 The aim of the present study
was to investigate the association between atrial fibrillation and
cognition. In the same cohort, we examined relations between atrial
fibrillation and cognitive function, taking stroke and possible
confounders such as high BP, diabetes, myocardial infarction, and
ejection fraction into account.
![]()
Subjects and Methods
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
A longitudinal health survey focusing on
cardiovascular risk factors was started in the early
1970s in Uppsala, Sweden. The original cohort was defined as
all 50-year-old men, ie, those born in 19201924, who lived in
Uppsala at that time. The baseline examination included
information on socioeconomic factors; measurements of BP, blood
glucose, serum insulin, lipids and lipoproteins; and recording
of ECG.3 The participation rate was 82%
(n=2322). Primary preventive treatment was initiated in subjects at
high risk for vascular disease.4 Twenty years
later, 448 men had died, and 193 men had moved. Of the 1681 men still
alive and living in Uppsala county, 99 men died before being
asked and 361 men refused to participate. A total of 1221 men (65.2%
of all 1874 survivors) took part in the follow-up at age 70. This
examination covered analyses of several variables linked to
vascular disease. ECG was recorded in 1136 men, and
echocardiography was performed in the first
consecutive 584 men. All 1221 participants were invited to a testing of
cognitive functions, in which 999 men (82%) participated. For a total
of 952 men, both ECGs and cognitive test results were available. Four
hundred nineteen men took part both in the cognitive testing, the
ECG, and the echocardiographic examination.
Subjects with a stroke before the cognitive testing were
identified by data from the Swedish National Inpatient Register,
covering all diagnoses in hospitalized patients from 1970 and onward,
and/or by a positive answer to the question "Have you had a stroke:
cerebrovascular infarct or bleeding?" in connection with the testing.
The following diagnoses, according to the International
Classification of Diseases (ICD)-8 or ICD-9, were used for
classification of stroke: intracerebral
hemorrhage (431), thromboembolic stroke (433 and 434),
transient ischemic attack (435), and acute "ill-defined"
cerebrovascular disease (436). A previous myocardial infarction was
identified through the Inpatient Register, ICD diagnoses 410 to 412. As
previously described,2 24-hour ambulatory BP was
monitored with Accutracker 2 equipment (Suntech Medical Instruments
Inc). An oral glucose tolerance test identified subjects with
diabetes according to the classification of the National Diabetes Data
Group.5 Resting standard 12-lead ECGs were
obtained. They were read and coded by the same physician (L.L.) with
regard to presence or absence of atrial fibrillation. Comprehensive
2-dimensional and Doppler echocardiography was
performed with a Hewlett Packard Sonos 1500 cardiac ultrasound unit, as
described previously.6 A 2.5-MHz transducer was
used for the majority of 2-dimensional, M-mode, and pulsed-wave
Doppler examinations. All subjects were examined by 1 experienced
physician (B.A.). As a measurement of left ventricular
systolic function, ejection fraction was computed according to
the Teichholz M-mode formula.7 Treatment with
agents affecting BP, irrespective of indication (ie, ß-blockers,
calcium antagonists, angiotensin-converting
enzyme inhibitors, diuretics, and
-blockers) and
treatment with digoxin, low-dose aspirin, and warfarin were registered
in a questionnaire. Educational level was stratified as low (elementary
school only, 6 to 7 years), medium (secondary school), or high
(university studies). Main previous occupational level was divided into
3 categories: low (manual workers), medium (foremen, clerks, and
salesmen), and high (major professionals, business managers).
The psychometric testing included the Trail Making Tests (TMTs)
A (n=998) and B (n=996)8 and the MiniMental
State Examination (MMSE)9 (n=891, since it was
added to the protocol after the start). The TMTs were selected to
assess speed and shifting capacity, which are measurements of
subcorticofrontal function, among others.10 The
MMSE is an instrument widely used in the screening for cognitive
disorders. Standardized procedures from published manuals were used in
the administration and evaluation. The maximum time set for the TMTs
was 4 minutes. After a logarithmic transformation of the test results,
a z transformation was applied, and a composite cognitive
score was calculated for each subject as the sum of the z
scores, divided by the number of tests performed. Thus, ±0.0 is equal
to the mean result in the population; +1.0 is a result 1 SD over the
mean score. Informed consent was obtained from the participants after
the nature of the procedures had been fully explained. The study was
approved by the Ethics Committee at Uppsala University.
Values are expressed as means and adjusted means or, in case of
skewed distributions (MMSE, TMT), as median values. Student's unpaired
t test was applied for comparisons between independent
groups, the
2 test was used for
analysis of relations between categorical variables, and
linear relations were examined with Pearson's correlation coefficient.
ANCOVA was applied in multivariate models with
continuous dependent variables, and logistic regression was used
when outcome variables were binary. All analyses were
adjusted for age. The analyses of determinants of cognitive
function were adjusted for age and educational (low, medium, high) and
occupational (low, medium, high) levels.
![]()
Results
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
Representativity
The nonparticipating survivors (n=653) had significantly higher
concentrations of blood glucose, serum insulin, and
triglycerides at the baseline examination at age 50 years
than the participants in the follow-up (n=1221). BP levels, rates of
atrial fibrillation, and socioeconomic factors were equal between the
groups. The 448 men who died during follow-up had a lower educational
level and markedly higher BP, blood glucose, serum insulin, and lipids
at baseline than the survivors. The 952 men who took part in the
cognitive tests and the ECG did not differ from the other men
investigated (n=269) with regard to rates of myocardial infarction,
stroke, atrial fibrillation, treatment, previous occupational level, or
mean 24-hour diastolic BP. In nonparticipants, diabetes was
more frequent (21.5%) than in participants (13.1%;
P=0.001), and slightly more nonparticipants than
participants had low levels of education (66% versus 54%;
P=NS).
Characteristics of the participants (n=952) are presented
in Table 1
.
Eighty-four men had suffered a stroke before the testing, and 44 men
(4.6%) had atrial fibrillation. One third of the cohort were treated
with antihypertensive agents, irrespective of indication. The median
score in the MMSE was 29 points, and 45 men (5.3%) scored <26 points.
Measurements of ejection fraction were available in 358 men. They were
equal to the others regarding all variables, except that they were
older.
View this table:
[in a new window]
Table 1. Description of the Study Cohort
(n=952)
As shown in Table 2
,
men with a previous stroke (n=84) had a higher rate of atrial
fibrillation and myocardial infarction and lower ejection fraction than
the stroke-free participants. Twenty-four-hour diastolic BP
and the rate of diabetes did not differ significantly between groups.
Characteristics of men with atrial fibrillation (n=44) are
presented in Table 3
. They had higher 24-hour
diastolic BP and heart rate and a higher rate of diabetes
than the other men.
View this table:
[in a new window]
Table 2. Characteristics of Participants With
Stroke
View this table:
[in a new window]
Table 3. Characteristics of Participants With Atrial
Fibrillation
As previously described, age, education, occupation, high 24-hour
diastolic BP, and diabetes were independent determinants of
low cognitive function.2 Participants with
antihypertensive treatment performed equal to the rest of the cohort.
Neither previous myocardial infarction (n=92) nor low ejection fraction
was associated with impaired cognitive results independent of atrial
fibrillation (data not shown).
Stroke patients had lower results on the MMSE and the TMTs; the
adjusted mean cognitive score was -0.16±0.08 versus+0.15±0.03 in
stroke-free participants (P=0.0002), ie, a difference of
0.31 SD (Table 4
). Stroke
is a possible intermediate in the relation between atrial fibrillation
and low cognitive function. Therefore, separate analyses were
made with and without stroke patients. In the total population, men
with atrial fibrillation had lower adjusted cognitive score
(-0.26±0.11) than men without atrial fibrillation (+0.14±0.03;
P=0.0003) (Table 5
). Exclusion of
participants with stroke did not change this relationship; cognitive
score was -0.24±0.12 in the 36<\+aq;D> men with atrial fibrillation
and +0.17±0.03 in men without atrial fibrillation
(P=0.0001), ie, a difference of 0.41 SD (Table 5
). Results
in the MMSE and in the TMTs were equally affected. The relationship
between atrial fibrillation and low cognitive score was similar after
adjustment for 24-hour diastolic BP and heart rate,
diabetes, ejection fraction, and antihypertensive treatment. Men with
atrial fibrillation and concomitant antihypertensive treatment (n=29)
performed equal to the other 15 men with atrial fibrillation (-0.37
versus -0.48; P=NS). Eight men had the combination of
stroke and atrial fibrillation. Their adjusted mean cognitive score was
-0.38±0.32, and the mean score in stroke patients without atrial
fibrillation was -0.28±0.12 (P=0.755). Only 3 subjects had
atrial fibrillation at age 50 years; their mean cognitive score was
-0.27 (P=NS compared with the rest of the cohort).
View this table:
[in a new window]
Table 4. Cognitive Performance in
Stroke
View this table:
[in a new window]
Table 5. Cognitive Performance in Atrial
Fibrillation
Men with atrial fibrillation who were treated with digoxin (n=27)
performed markedly better than those without treatment (n=9) (Table 6
). The difference remained
highly significant after adjustment for 24-hour diastolic
BP, heart rate, and diabetes. Ejection fraction did not differ between
treated and untreated men and was not included in the model because of
the small number. Test results did not differ in men without atrial
fibrillation with regard to treatment with digoxin. In those with
atrial fibrillation, test results were equal between men treated with
low-dose aspirin or warfarin (n=17) and untreated men (n=21) and
between men with and without antihypertensive treatment.
View this table:
[in a new window]
Table 6. Digoxin Treatment in Atrial Fibrillation and
Cognitive Performance
![]()
Discussion
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
In these elderly men, those with atrial fibrillation had lower
cognitive function independent of socioeconomic factors, 24-hour
diastolic BP, diabetes, and ejection fraction, even after
exclusion of subjects with a previous stroke. The difference in the
mean adjusted cognitive z score between stroke-free men with
and without atrial fibrillation was 0.41 SD, ie, somewhat higher than
the difference between men with and without a previous manifest stroke
(0.31 SD). In men with atrial fibrillation, digoxin treatment was
associated with better cognitive performance. This cohort
consisted of community-living men with few cases of cognitive
impairment; only 5.3% had a score of <26 points on the MMSE, which is
a low rate compared with other populations, eg, the Rotterdam Study
cohort.11 Our cohort is likely to be healthier
than a general population since nonresponders had a lower educational
level and higher serum concentrations of glucose, insulin, and
triglycerides at baseline. Furthermore, special efforts to
treat vascular risk factors had been taken since the baseline
examination. Thus, our participants probably were selected with regard
to both a decreased vascular risk and a higher cognitive function, ie,
factors with negative relation to the outcome. For this reason the
relationship between atrial fibrillation and low cognitive function may
be different in a general population.
![]()
Acknowledgments
This study was supported by grants from the Swedish Medical
Research Council (grant 5446), the King Gustav V and Queen Victoria
Foundation, the Foundation of Old Servants, the Alzheimer
Foundation, the Dementia Foundation in Sweden, the Swedish Stroke
Foundation, and the Swedish Hypertension Society. We are grateful to
Gun-Britt Ångman for excellent coordination and care of the study
participants.
![]()
References
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
1.
Skoog I, Nilsson L, Palmertz B, Andreasson L-A,
Svanborg A. A population-based study of dementia in 85-year-olds.
N Engl J Med. 1993;328:153158.
This article has been cited by other articles:
![]() |
S. Knecht, C. Oelschlager, T. Duning, H. Lohmann, J. Albers, C. Stehling, W. Heindel, G. Breithardt, K. Berger, E. B. Ringelstein, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy Eur. Heart J., September 1, 2008; 29(17): 2125 - 2132. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Goette and R. C. Braun-Dullaeus Atrial fibrillation is associated with impaired cognitive function and hippocampal atrophy: silent cerebral ischaemia vs. Alzheimer's disease? Eur. Heart J., September 1, 2008; 29(17): 2067 - 2069. [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, R. C. Petersen, S. S. Cha, K. R. Bailey, B. J. Gersh, G. Casaclang-Verzosa, W. P. Abhayaratna, J. B. Seward, T. Iwasaka, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort Eur. Heart J., August 2, 2007; 28(16): 1962 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rastas, A. Verkkoniemi, T. Polvikoski, K. Juva, L. Niinisto, K. Mattila, E. Lansimies, T. Pirttila, and R. Sulkava Atrial Fibrillation, Stroke, and Cognition: A Longitudinal Population-Based Study of People Aged 85 and Older Stroke, May 1, 2007; 38(5): 1454 - 1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Park, A. Hildreth, R. Thomson, and J. O'Connell Non-valvular atrial fibrillation and cognitive decline: a longitudinal cohort study Age Ageing, March 1, 2007; 36(2): 157 - 163. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Weigl, A. Moritz, B. Steinlechner, I. Schmatzer, B. Mora, R. Fakin, D. Zimpfer, H. J. Ankersmit, C. Khazen, and M. Dworschak Neuronal injury after repeated brief cardiac arrests during internal cardioverter defibrillator implantation is associated with deterioration of cognitive function. Anesth. Analg., August 1, 2006; 103(2): 403 - 9, table of contents. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, K. R. Bailey, W. P. Abhayaratna, J. B. Seward, and T. S.M. Tsang Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence Circulation, July 11, 2006; 114(2): 119 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Chung, L. Shemanski, D. G. Sherman, H. L. Greene, D. B. Hogan, J. C. Kellen, S. G. Kim, L. W. Martin, Y. Rosenberg, D. G. Wyse, et al. Functional Status in Rate- Versus Rhythm-Control Strategies for Atrial Fibrillation: Results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1891 - 1899. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rowan, C.M. Morris, S. Stephens, C. Ballard, H. Dickinson, H. Rao, B.K. Saxby, A.T. McLaren, R.N. Kalaria, and R.A. Kenny Impact of Hypertension and Apolipoprotein E4 on Poststroke Cognition in Subjects >75 Years of Age Stroke, September 1, 2005; 36(9): 1864 - 1868. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Elias, L. M. Sullivan, R. B. D'Agostino, P. K. Elias, A. Beiser, R. Au, S. Seshadri, C. DeCarli, and P. A. Wolf Framingham Stroke Risk Profile and Lowered Cognitive Performance Stroke, February 1, 2004; 35(2): 404 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.C. de la Torre Alzheimer Disease as a Vascular Disorder: Nosological Evidence Stroke, April 1, 2002; 33(4): 1152 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Henon, I. Durieu, D. Guerouaou, F. Lebert, F. Pasquier, and D. Leys Poststroke dementia: Incidence and relationship to prestroke cognitive decline Neurology, October 9, 2001; 57(7): 1216 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Chugh, J. L. Blackshear, W.-K. Shen, S. C. Hammill, and B. J. Gersh Epidemiology and natural history of atrial fibrillation: clinical implications J. Am. Coll. Cardiol., February 1, 2001; 37(2): 371 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-E. de Leeuw, J. C. de Groot, M. Oudkerk, J. A. Kors, A. Hofman, J. van Gijn, and M. M. B. Breteler Atrial fibrillation and the risk of cerebral white matter lesions Neurology, May 9, 2000; 54(9): 1795 - 1801. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Ezekowitz Atrial Fibrillation: The Epidemic of the New Millennium Ann Intern Med, October 5, 1999; 131(7): 537 - 538. [Full Text] [PDF] |
||||
![]() |
R. Rozzini, T. Sabatini, M. Trabucchi, L. Kilander, and M. Boberg Chronic Atrial Fibrillation and Low Cognitive Function • Response Stroke, January 1, 1999; 30(1): 190 - 191. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |